HK6993A - New quinazoline derivatives, process for their production and pharmaceutical compositions comprising them - Google Patents

New quinazoline derivatives, process for their production and pharmaceutical compositions comprising them Download PDF

Info

Publication number
HK6993A
HK6993A HK69/93A HK6993A HK6993A HK 6993 A HK6993 A HK 6993A HK 69/93 A HK69/93 A HK 69/93A HK 6993 A HK6993 A HK 6993A HK 6993 A HK6993 A HK 6993A
Authority
HK
Hong Kong
Prior art keywords
nujol
tetrahydro
compound
dioxoquinazolin
ethyl
Prior art date
Application number
HK69/93A
Other languages
German (de)
English (en)
French (fr)
Inventor
Masashi Hashimoto
Teruo Oku
Yoshikuni Ito
Takayuki Namiki
Kozo Sawada
Chiyoshi Kasahara
Yukihisa Baba
Original Assignee
Fujisawa Pharmaceutical Co., Ltd.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Fujisawa Pharmaceutical Co., Ltd. filed Critical Fujisawa Pharmaceutical Co., Ltd.
Publication of HK6993A publication Critical patent/HK6993A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/12—Ophthalmic agents for cataracts
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72—Quinazolines; Hydrogenated quinazolines
    • C07D239/78—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 2
    • C07D239/80—Oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72—Quinazolines; Hydrogenated quinazolines
    • C07D239/95—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in positions 2 and 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72—Quinazolines; Hydrogenated quinazolines
    • C07D239/95—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in positions 2 and 4
    • C07D239/96—Two oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D285/00—Heterocyclic compounds containing rings having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by groups C07D275/00 - C07D283/00
    • C07D285/15—Six-membered rings
    • C07D285/16—Thiadiazines; Hydrogenated thiadiazines
    • C07D285/18—1,2,4-Thiadiazines; Hydrogenated 1,2,4-thiadiazines
    • C07D285/20—1,2,4-Thiadiazines; Hydrogenated 1,2,4-thiadiazines condensed with carbocyclic rings or ring systems
    • C07D285/22—1,2,4-Thiadiazines; Hydrogenated 1,2,4-thiadiazines condensed with carbocyclic rings or ring systems condensed with one six-membered ring
    • C07D285/24—1,2,4-Thiadiazines; Hydrogenated 1,2,4-thiadiazines condensed with carbocyclic rings or ring systems condensed with one six-membered ring with oxygen atoms directly attached to the ring sulfur atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Emergency Medicine (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Reproductive Health (AREA)
  • Neurosurgery (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
HK69/93A 1985-10-07 1993-01-28 New quinazoline derivatives, process for their production and pharmaceutical compositions comprising them HK6993A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB858524663A GB8524663D0 (en) 1985-10-07 1985-10-07 Quinazoline derivatives

Publications (1)

Publication Number Publication Date
HK6993A true HK6993A (en) 1993-02-05

Family

ID=10586291

Family Applications (1)

Application Number Title Priority Date Filing Date
HK69/93A HK6993A (en) 1985-10-07 1993-01-28 New quinazoline derivatives, process for their production and pharmaceutical compositions comprising them

Country Status (23)

Country Link
US (2) US4734419A (enExample)
EP (1) EP0218999B1 (enExample)
JP (3) JPS6296476A (enExample)
KR (1) KR940007270B1 (enExample)
CN (1) CN1017242B (enExample)
AT (1) ATE60761T1 (enExample)
AU (1) AU596611B2 (enExample)
CA (1) CA1289139C (enExample)
DE (1) DE3677452D1 (enExample)
DK (1) DK158838C (enExample)
ES (1) ES2021266B3 (enExample)
FI (1) FI90234C (enExample)
GB (1) GB8524663D0 (enExample)
GR (1) GR3001502T3 (enExample)
HK (1) HK6993A (enExample)
HU (1) HU196972B (enExample)
IE (1) IE59309B1 (enExample)
IL (1) IL80213A (enExample)
NO (1) NO171785C (enExample)
SG (1) SG112092G (enExample)
SU (1) SU1588283A3 (enExample)
UA (1) UA5562A1 (enExample)
ZA (1) ZA867043B (enExample)

Families Citing this family (55)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8524663D0 (en) * 1985-10-07 1985-11-13 Fujisawa Pharmaceutical Co Quinazoline derivatives
MX7829A (es) * 1986-08-21 1993-08-01 Pfizer Quinazolindionas y piridopirimindionas y procedimiento para su preparacion
US4889851A (en) * 1986-11-21 1989-12-26 Fujisawa Pharmaceutical Co, Ltd. Benzothiadiazine compounds, and pharmaceutical composition comprising the same
US4931440A (en) * 1987-07-29 1990-06-05 Fujisawa Pharmaceutical Company, Ltd. Uricosuric composition
EP0335979A4 (en) * 1987-09-16 1992-02-26 Taiho Pharmaceutical Company, Limited Thienopyrimidine derivatives
JP2621460B2 (ja) * 1988-02-29 1997-06-18 藤沢薬品工業株式会社 利尿または降圧剤
US5324747A (en) * 1992-07-15 1994-06-28 Hoffmann-La Roche Inc. N-substituted anilines, inhibitors of phospholipases A2
EP0662962A1 (en) * 1992-09-28 1995-07-19 Pfizer Inc. Substituted pyrimidines for control of diabetic complications
DE19532052C2 (de) * 1995-08-31 1998-11-19 Clariant Gmbh Verfahren zur Herstellung von Chinazolinderivaten
EP0847382B1 (de) * 1995-08-31 2000-12-20 Clariant GmbH Monoester der carboxymethylenanthranilsäuren und verfahren zu ihrer herstellung
EP0781767B1 (en) * 1995-12-26 2001-09-05 Sumitomo Chemical Company, Limited Process for producing isatoic anhydrides
WO1997024335A1 (en) * 1995-12-28 1997-07-10 Fuji Chemical Industry Co., Ltd. Process for the preparation of 3-dihalobenzyl-2,4-quinazolinedione derivatives
DE69701647T2 (de) * 1996-02-01 2000-09-07 Sumitomo Chemical Co., Ltd. Verfahren zur Herstellung von Dioxochinazolinen
DE19650975A1 (de) * 1996-12-09 1998-06-10 Basf Ag Neue heterocyclisch substituierte Benzamide und deren Anwendung
EP1222927B1 (en) * 1997-04-15 2013-11-20 Csir Pharmaceutical compositions having appetite suppressant activity
US6444816B1 (en) 1997-10-27 2002-09-03 Dr. Reddy's Research Foundation Fused 7-oxo-pyrimidinyl compounds, preparation, composition and use thereof
IL137128A0 (en) * 1998-01-30 2001-07-24 R Tech Ueno Ltd Ophthalmic compositions containing tetrahydroquinazoline derivatives
AU2129500A (en) * 1999-01-25 2000-08-07 Fujisawa Pharmaceutical Co., Ltd. Eye drops
MXPA00010193A (es) 1999-02-18 2002-04-17 R Tech Ueno Ltd Composicion para el tratamiento de transtornos de secrecion externa excepto hipolagrimeo.
CN1349512A (zh) * 1999-03-09 2002-05-15 藤泽药品工业株式会社 喹唑啉衍生物或其盐的制备方法
US7230000B1 (en) * 1999-10-27 2007-06-12 Cytokinetics, Incorporated Methods and compositions utilizing quinazolinones
GB2355657B (en) * 1999-10-27 2004-07-28 Phytopharm Plc Inhibitors Of Gastric Acid Secretion
US6545004B1 (en) 1999-10-27 2003-04-08 Cytokinetics, Inc. Methods and compositions utilizing quinazolinones
US6380200B1 (en) 1999-12-07 2002-04-30 Pfizer, Inc. Combination of aldose reductase inhibitors and selective serotonin reuptake inhibitors for the treatment of diabetic complications
GB2363985B (en) * 2000-06-30 2004-09-29 Phytopharm Plc Extracts,compounds & pharmaceutical compositions having anti-diabetic activity and their use
OA12413A (en) 2000-11-30 2004-09-30 Pfizer Prod Inc Combination of GABA agonists and aldose reductase inhibitors.
JP4273406B2 (ja) * 2001-06-01 2009-06-03 小野薬品工業株式会社 アルドース還元酵素阻害剤を有効成分とする脱髄性疾患または脱髄を伴う疾患治療剤
JP2005529076A (ja) * 2002-02-15 2005-09-29 サイトキネティクス・インコーポレーテッド キナゾリノンの合成
AU2003217676B2 (en) 2002-02-22 2009-06-11 Takeda Pharmaceutical Company Limited Active agent delivery systems and methods for protecting and administering active agents
AU2003223786A1 (en) * 2002-05-09 2003-11-11 Cytokinetics, Inc. Compounds, methods and compositions
AU2003270015A1 (en) 2002-05-09 2003-12-02 Cytokinetics, Inc. Compounds, compositions, and methods
EP1507534A4 (en) * 2002-05-10 2006-11-08 Cytokinetics Inc COMPOUNDS, COMPOSITIONS AND METHODS
EP1513820A4 (en) * 2002-05-23 2006-09-13 Cytokinetics Inc COMPOUNDS, COMPOSITIONS AND METHODS
JP2005538062A (ja) * 2002-06-14 2005-12-15 サイトキネティクス・インコーポレーテッド 化合物、組成物、および方法
JP2006501201A (ja) * 2002-07-23 2006-01-12 サイトキネティクス・インコーポレーテッド 化合物、組成物および方法
JP2005536553A (ja) * 2002-08-21 2005-12-02 サイトキネティクス・インコーポレーテッド 化合物、組成物および方法
JP2006501306A (ja) * 2002-09-30 2006-01-12 サイトキネティクス・インコーポレーテッド 化合物、組成物および方法
JP2007510652A (ja) * 2003-11-03 2007-04-26 サイトキネティクス・インコーポレーテッド ピリミジン−４−オン化合物、組成物、および方法
WO2005046588A2 (en) * 2003-11-07 2005-05-26 Cytokinetics, Inc. Compounds, compositions, and methods
JP2007513154A (ja) * 2003-12-08 2007-05-24 サイトキネティクス・インコーポレーテッド 化合物、組成物及び方法
US20070010537A1 (en) * 2004-08-20 2007-01-11 Kazumasa Hamamura Fused pyramidine derivative and use thereof
US20110092566A1 (en) * 2004-11-19 2011-04-21 Srivastava Satish K Treatment of cancer with aldose reductase inhibitors
EP2394983B1 (en) * 2006-07-19 2014-09-24 E.I. Du Pont De Nemours And Company Process for making 3-substituted 2-amino-5-halobenzamides
ES2371393T3 (es) 2007-03-12 2011-12-30 Zadec Aps Extracto antidiabético de rooibos.
EP2848252A3 (en) 2007-03-23 2015-06-17 The Board of Regents of the University of Texas System Aldose reductase inhibitors for use in treating uveitis
CA2695331A1 (en) * 2007-08-03 2009-02-12 F. Hoffmann-La Roche Ag Pyridinecarboxamide and benzamide derivatives as taar1 ligands
US20090270490A1 (en) * 2008-04-24 2009-10-29 The Board Of Regents Of The University Of Texas System Methods involving aldose reductase inhibition
CN102219759B (zh) * 2010-04-16 2013-07-24 中国科学院上海药物研究所 芳基甲酰胺类化合物及其制备方法、药物组合物和用途
US8785483B2 (en) 2010-12-23 2014-07-22 The Board Of Regents Of The University Of Texas System Methods for treating COPD
WO2014182945A1 (en) 2013-05-10 2014-11-13 Nimbus Apollo, Inc. Acc inhibitors and uses thereof
BR112015028214A2 (pt) 2013-05-10 2017-07-25 Nimbus Apollo Inc inibidores de acc e usos dos mesmos
EP2994138A4 (en) 2013-05-10 2016-12-28 Nimbus Apollo Inc ACC-HEMMER AND USES THEREOF
TW201623257A (zh) 2014-05-09 2016-07-01 奧利安公司 藥理活性之喹唑啉二酮衍生物
US12090142B2 (en) 2018-02-22 2024-09-17 Board Of Regents, The University Of Texas System Combination therapy for the treatment of cancer
CN111499616B (zh) * 2020-05-07 2022-07-22 盐城工学院 一种芳杂环取代的喹唑啉酮衍生物及其合成方法与应用

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4016166A (en) * 1973-12-14 1977-04-05 Hisamitsu Pharmaceutical Co., Inc. 1-Nitrophenylquinazoline-2,4(1H,3H)-diones
DE2652144A1 (de) * 1976-11-16 1978-05-18 Merck Patent Gmbh Neue chinazolindione
CA1161036A (en) * 1980-05-15 1984-01-24 Masayuki Ishikawa Quinazoline-dione compounds, process for production thereof and pharmaceutical use thereof
DE3172006D1 (en) * 1980-05-22 1985-10-03 Masayuki Ishikawa Novel quinazoline-dione compounds, process for production thereof and pharmaceutical use thereof
JPS58159480A (ja) * 1982-03-17 1983-09-21 Chugai Pharmaceut Co Ltd 新規なフエニルピペラジン誘導体
DD232702A1 (de) * 1982-09-20 1986-02-05 Adw Ddr Verfahren zur herstellung von 1,2,3,4-tetrahydrochinazolin-2,4-dion-essigsaeuren, deren salzen und estern
US4490374A (en) * 1982-09-30 1984-12-25 Ortho Pharmaceutical Corporation 5,6-Dialkoxy-3,4-optionally substituted-2(1H)quinazolinones, composition and method of use
JPS59186963A (ja) * 1983-04-08 1984-10-23 Chugai Pharmaceut Co Ltd 新規なフエニルピペラジン誘導体
GB8524663D0 (en) * 1985-10-07 1985-11-13 Fujisawa Pharmaceutical Co Quinazoline derivatives

Also Published As

Publication number Publication date
DK158838C (da) 1991-01-14
FI863917L (fi) 1987-04-08
AU596611B2 (en) 1990-05-10
JPH05366B2 (enExample) 1993-01-05
US4883800A (en) 1989-11-28
NO171785C (no) 1993-05-05
KR870003998A (ko) 1987-05-06
SG112092G (en) 1992-12-24
ES2021266B3 (es) 1991-11-01
JPS6296476A (ja) 1987-05-02
HUT41747A (en) 1987-05-28
IL80213A0 (en) 1987-01-30
US4734419A (en) 1988-03-29
FI90234C (fi) 1994-01-10
IE59309B1 (en) 1994-02-09
IL80213A (en) 1991-06-30
DE3677452D1 (de) 1991-03-14
NO863980D0 (no) 1986-10-06
HU196972B (en) 1989-02-28
GR3001502T3 (en) 1992-11-23
GB8524663D0 (en) 1985-11-13
JPH0794447B2 (ja) 1995-10-11
EP0218999A2 (en) 1987-04-22
CN86106984A (zh) 1987-05-20
DK158838B (da) 1990-07-23
JPH0482148B2 (enExample) 1992-12-25
JPH01125322A (ja) 1989-05-17
ATE60761T1 (de) 1991-02-15
UA5562A1 (uk) 1994-12-28
CN1017242B (zh) 1992-07-01
AU6358986A (en) 1987-04-09
IE862520L (en) 1987-04-07
ZA867043B (en) 1987-07-29
KR940007270B1 (en) 1994-08-12
FI863917A0 (fi) 1986-09-29
FI90234B (fi) 1993-09-30
CA1289139C (en) 1991-09-17
DK459086A (da) 1987-04-08
DK459086D0 (da) 1986-09-25
EP0218999A3 (en) 1988-01-13
JPH01131164A (ja) 1989-05-24
NO171785B (no) 1993-01-25
SU1588283A3 (ru) 1990-08-23
NO863980L (no) 1987-04-08
EP0218999B1 (en) 1991-02-06

Similar Documents

Publication Publication Date Title
EP0218999B1 (en) New quinazoline derivatives, process for their production and pharmaceutical compositions comprising them
FI114023B (fi) Menetelmä uusien terapeuttisesti käyttökelpoisten kinatsolinonien valmistamiseksi
US3702849A (en) 4-(isoquinolin-1-yl) piperazine-1-carboxylic acid esters
US4818756A (en) 2-pyrimidinyl-1-piperazine derivatives, processes for their preparation and medicaments containing them
US5430148A (en) Antiproliferative quinazolines
NZ231588A (en) Quinazoline-4-one derivatives, medicaments
JP5216341B2 (ja) 血管新生阻害活性を有する新規オキサジアゾール誘導体およびチアジアゾール誘導体
US20030130278A1 (en) Alkynylated fused ring pyrimidine compounds
US3993656A (en) 1,8-Naphthyridine compounds
HU207999B (en) Process for producing quinazolin-3-alkanoic acids and pharmaceutical compositions containing them
US5019587A (en) Bicyclic carboxamides, compositions containing same and use thereof
US4782055A (en) Imidazopyridine compounds useful in the treatment of ulcers
WO2003033478A1 (en) Alkynylated fused ring pyrimidine compounds as matrix metalloprotease-13 inhibitors
US5679677A (en) Heterocyclic carbamates, process for their preparation and medicaments
EP0517357A1 (en) Angiotensin II antagonists incorporating a substituted indole or dihydroindole
JP5006505B2 (ja) 緑内障および近視を処置するためのベンゾ［ｇ］キノリン誘導体
EP0138491A2 (en) Substituted 2(1H)-quinazolinone-1-alkanoic acids and esters
US4608375A (en) Quinazolinone derivatives, processes for the preparation thereof and pharmaceutical composition comprising the same
US5187276A (en) 2-pyrimidinyl-1-piperazine derivatives
WO1994003439A1 (en) Antiproliferative tricyclic compounds
EP0309765A2 (en) 1(2H)-Phthalazinones as cytoprotective agents
CA2100164A1 (en) 2,4-dioxo-pyrido[2,3-d]pyrimidine-3-acetic acids and esters and salts thereof
CZ20001981A3 (cs) 2-Aryl-8-oxodihydropurinové deriváty, způsob jejich přípravy, farmaceutické prostředky které je obsahují a jejich meziprodukty
EP1465878A1 (en) Alkynylated fused ring pyrimidine compounds as matrix metalloprotease-13 inhibitors

Legal Events

Date Code Title Description
PC Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee)